WPA
IBRX icon

Winning Points Advisors’s ImmunityBio IBRX Stock Holding History

Winning Points Advisors’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.24M Hold
722,373
– – 2.99% 7
2025
Q4 		$509K Buy
+722,373
New +$1.64M 0.54% 27
2024
Q3 		$143K Buy
+89,396
New +$414K 0.24% 31
2024
Q1 		$466K Hold
92,786
– – 0.72% 21
2023
Q4 		$466K Buy
92,786
+3,390
+4% +$10.6K 0.72% 21
2023
Q3 		$143K Sell
89,396
-3,390
-4% -$6.81K 0.25% 30
2023
Q2 		$466K Sell
92,786
-158,400
-63% -$448K 0.72% 21
2023
Q1 		$461K Buy
251,186
+8,600
+4% +$26.7K 0.51% 29
2022
Q4 		$1.23M Sell
242,586
-8,970
-4% -$49.3K 1.56% 14
2022
Q3 		$1.39M Buy
251,556
+14,600
+6% +$66.5K 1.7% 14
2022
Q2 		$879K Buy
236,956
+176,830
+294% +$710K 0.97% 23
2022
Q1 		$339K Buy
+60,126
New +$369K 0.26% 47
2021
Q4 		– Sell
-43,958
Closed -$428K – 74
2021
Q3 		$428K Buy
43,958
+2,483
+6% +$27.3K 0.31% 45
2021
Q2 		$593K Buy
41,475
+1,475
+4% +$24.4K 0.44% 40
2021
Q1 		$974K Hold
40,000
– – 0.73% 32
2020
Q4 		$533K Buy
+40,000
New +$385K 0.43% 39

Other funds holding IBRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Winning Points Advisors's IBRX Position: Q1 2026 in Review

Winning Points Advisors held its ImmunityBio (IBRX) position steady in Q1 2026 at 722,373 shares worth $2.24M. The position accounts for 2.99% of the portfolio, ranked #7.

Winning Points Advisors first reported a position in IBRX in Q4 2020 and has held it in 16 quarters since. 386 funds tracked by Wall St. Rank hold IBRX as of Q1 2026.

  • Winning Points Advisors held 722,373 shares of ImmunityBio worth $2.24M as of Q1 2026.
  • Winning Points Advisors left its ImmunityBio share count unchanged in Q1 2026.
  • ImmunityBio made up 2.99% of Winning Points Advisors's portfolio in Q1 2026, its #7 holding.
  • Winning Points Advisors first reported a position in ImmunityBio in Q4 2020 and has held it in 16 quarters since.
  • 386 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2026.

Based on Winning Points Advisors's 13F filing for Q1 2026, filed 30 Jun 2026.